QURE
uniQure N.V.
Set alert
- YTD
- +3.76%
- 1 year
- -63.41%
- Open
- 25.11
- Prev close
- 25.30
- Mkt cap
- 1.72B
- Vol
- 1.82M
- Avg vol
- 1.99M
- EPS
- -4.03
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 23.56
- High
- 25.21
- Forward P/E
- -8.36
- Beta
- 1.06
- Short ratio
- 2.55
- Inst. own
- 98.44%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 35.04
- 200-d avg
- 29.64
- 1y target
- 60.18
Key statistics
- Market cap
- 1.72B
- Enterprise value
- 1.50B
- Trailing P/E
- 0.00
- Forward P/E
- -8.36
- PEG ratio
- 0.00
- Price / sales
- 92.24
- Price / book
- 5.31
- EPS (TTM)
- -4.03
- Beta
- 1.06
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 18.67M
- Revenue growth
- 11.00%
- Free cash flow
- -77.58M
- Total cash
- 810.33M
- Total debt
- 552.17M
- Return on equity
- -157.61%
- Shares outstanding
- 69.37M
- Short % of float
- 12.75%
- 50-day average
- 35.04
- 200-day average
- 29.64
Analyst view
Consensus: strong buy
- Target (low)
- 27.90
- Target (mean)
- 60.18
- Target (high)
- 91.24
- Strong buy1
- Buy10
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate -0.81964.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -0.91521 | — | — | — |
| Jul 29, 2026 | Jun 30, 2026 | -0.82228 | -1.22 | -0.40 | -48.37% |
| May 5, 2026 | Mar 31, 2026 | -0.88 | -0.85 | +0.03 | +3.41% |
| Mar 2, 2026 | Dec 31, 2025 | -0.93 | -0.56 | +0.37 | +39.78% |
| Nov 10, 2025 | Sep 30, 2025 | -0.85 | -1.38 | -0.53 | -62.35% |
| Jul 29, 2025 | Jun 30, 2025 | -0.89 | -0.69 | +0.20 | +22.47% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 2026 | Barclays | down | Overweight | Equal-Weight |
| Oct 2, 2026 | RBC Capital | main | Outperform | Outperform |
| Sep 30, 2026 | Goldman Sachs | main | Neutral | Neutral |
| Jul 30, 2026 | Wells Fargo | main | Overweight | Overweight |
| Jul 30, 2026 | Wolfe Research | up | Peer Perform | Outperform |
| Jul 30, 2026 | Barclays | main | Overweight | Overweight |
About uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Netherlands
- Website
- uniqure.com
News
- 3 Promising Genomics Stocks to Add to Your Portfolio Now
- uniQure to Announce Third Quarter 2026 Financial Results
- Barclays Downgrades uniQure to Equal-Weight, Lowers Price Target to $28
- RBC Capital Maintains Outperform on uniQure, Lowers Price Target to $48
- Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $31
- Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Crude Oil Down 1%; US Job Openings Fall In August
- Why Is uniQure Stock Sinking on Tuesday?
- Dow Tumbles 100 Points; Carnival Posts Upbeat Q3 Earnings
Your note
Sign in to keep a note on QURE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABI-SAAB WALID | Officer | Conversion of Exercise of derivative security | Jun 29, 2026 | 148,235 |
| BALACHANDRAN MADHAVEN | Director | Conversion of Exercise of derivative security | Jun 16, 2026 | 43,254 |
| JACQUES RACHELLE SUZANNE | Director | Sale | Jun 10, 2026 | 33,903 |
| KAPUSTA MATTHEW C | Chief Executive Officer | Conversion of Exercise of derivative security | Jul 1, 2026 | 519,227 |
| KLEMT CHRISTIAN | Chief Financial Officer | Stock Award(Grant) | Mar 3, 2026 | 226,581 |
| MEEK DAVID D | Director | Sale | Jun 10, 2026 | 39,747 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 9.70% | 6,727,777 | 167.05M | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 7.02% | 4,867,755 | 120.87M | Jun 29, 2026 |
| RTW Investments LP | 5.68% | 3,941,572 | 97.87M | Jun 29, 2026 |
| State Street Corporation | 4.19% | 2,903,825 | 72.10M | Jun 29, 2026 |
| Aberdeen Group plc | 4.11% | 2,848,117 | 70.72M | Jun 29, 2026 |
| Blackrock Inc. | 2.71% | 1,877,453 | 46.62M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.93% | 2,031,760 | 50.45M | Sep 29, 2026 |
| abrdn Healthcare Investors | 1.79% | 1,240,256 | 30.80M | Jun 29, 2026 |
| J.P. Morgan Mutual Fd. Investment TRT-JPMorgan Growth Advantage Fd. | 1.78% | 1,237,920 | 30.74M | Jun 29, 2026 |
| JPMorgan Trust II-JPMorgan Mid Cap Growth Fund | 1.38% | 959,052 | 23.81M | Jun 29, 2026 |
| abrdn World Healthcare Fund | 1.14% | 792,575 | 19.68M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.09% | 758,041 | 18.82M | Jun 29, 2026 |